BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 30552477)

  • 1. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
    Lee HS; Kim MJ; An C
    Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
    Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM
    Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
    Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
    Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection.
    Shao S; Liang Y; Kuang S; Chen J; Shan Q; Yang H; Zhang Y; Wang B; J Fowler K; Wang J; B Sirlin C
    Bosn J Basic Med Sci; 2020 Aug; 20(3):401-410. PubMed ID: 31999940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
    Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
    Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LI-RADS Version 2018 Targetoid Appearances on Gadoxetic Acid-Enhanced MRI: Interobserver Agreement and Diagnostic Performance for the Differentiation of HCC and Non-HCC Malignancy.
    Min JH; Lee MW; Park HS; Lee DH; Park HJ; Lee JE; Park SJ; Kim SS; Park SH; Ha SY; Hwang JA; Cha DI; Park B
    AJR Am J Roentgenol; 2022 Sep; 219(3):421-432. PubMed ID: 35319906
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.
    Jiang H; Song B; Qin Y; Chen J; Xiao D; Ha HI; Liu X; Oloruntoba-Sanders O; Erkanli A; Muir AJ; Bashir MR
    Eur Radiol; 2021 Jun; 31(6):3638-3648. PubMed ID: 33245494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
    Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
    Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
    Wang Y; Zhu GQ; Zhou CW; Li N; Yang C; Zeng MS
    Eur Radiol; 2022 Aug; 32(8):5166-5178. PubMed ID: 35316365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
    Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
    Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter-reader agreement and imaging-pathology correlation of the LI-RADS M on gadoxetic acid-enhanced magnetic resonance imaging: efforts to improve diagnostic performance.
    Lim K; Kwon H; Cho J
    Abdom Radiol (NY); 2020 Aug; 45(8):2430-2439. PubMed ID: 32008112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
    Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
    Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
    Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
    J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma.
    Wu H; Liang Y; Wang Z; Tan C; Yang R; Wei X; Jiang X
    Acta Radiol; 2023 Mar; 64(3):926-935. PubMed ID: 35898164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.
    Xiao Y; Zheng X; Zhou C; Huang P; Wu F; Yang C; Zeng M
    Eur Radiol; 2023 Feb; 33(2):1412-1421. PubMed ID: 36112193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
    Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
    Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.